{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:09:00Z","timestamp":1782518940601,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,17]]},"DOI":"10.7759\/cureus.64717","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T09:54:12Z","timestamp":1721210052000},"source":"Crossref","is-referenced-by-count":2,"title":["Exploring the Therapeutic Potential of High Dose Co-amoxiclav (1 gm) in Different Clinical Conditions: A Review"],"prefix":"10.7759","author":[{"given":"Debasis","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Kanti Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitrajit","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatray","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/24.4.570","article-title":"Dosing of amoxicillin\/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group","volume":"24","author":"Calver AD","year":"1997","unstructured":"Calver AD, Walsh NS, Quinn PF, Baran C, Lonergan V, Singh KP, Orzolek WS. Dosing of amoxicillin\/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis. 1997, 24:570-4. 10.1093\/clind\/24.4.570","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4065\/74.3.290","article-title":"The penicillins","volume":"74","author":"Wright AJ","year":"1999","unstructured":"Wright AJ. The penicillins. Mayo Clin Proc. 1999, 74:290-307. 10.4065\/74.3.290","journal-title":"Mayo Clin Proc"},{"key":"ref3","article-title":"Clavulanic acid","author":"Uto LR","year":"2024","unstructured":"Uto LR, Gerriets V. Clavulanic acid. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00374-7","article-title":"Orally administered amoxicillin\/clavulanate: current role in outpatient therapy","volume":"10","author":"Veeraraghavan B","year":"2021","unstructured":"Veeraraghavan B, Bakthavatchalam YD, Sahni RD. Orally administered amoxicillin\/clavulanate: current role in outpatient therapy. Infect Dis Ther. 2021, 10:15-25. 10.1007\/s40121-020-00374-7","journal-title":"Infect Dis Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.07.015","article-title":"Introduction: historical perspective and development of amoxicillin\/clavulanate","volume":"30 Suppl 2","author":"Geddes AM","year":"2007","unstructured":"Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin\/clavulanate. Int J Antimicrob Agents. 2007, 30 Suppl 2:S109-12. 10.1016\/j.ijantimicag.2007.07.015","journal-title":"Int J Antimicrob Agents"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh050","article-title":"Augmentin (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent","volume":"53 Suppl 1","author":"White AR","year":"2004","unstructured":"White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004, 53 Suppl 1:i3-20. 10.1093\/jac\/dkh050","journal-title":"J Antimicrob Chemother"},{"key":"ref7","article-title":"Amoxicillin clavulanate","author":"Evans J","year":"2024","unstructured":"Evans J, Hanoodi M, Wittler M. Amoxicillin clavulanate. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.028","article-title":"Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage","volume":"26","author":"Huttner A","year":"2020","unstructured":"Huttner A, Bielicki J, Clements MN, Frimodt-M\u00f8ller N, Muller AE, Paccaud JP, Mouton JW. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020, 26:871-9. 10.1016\/j.cmi.2019.11.028","journal-title":"Clin Microbiol Infect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_a.9","article-title":"Determinants of the activity of beta-lactamase inhibitor combinations","volume":"31 Suppl A","author":"Livermore DM","year":"1993","unstructured":"Livermore DM. Determinants of the activity of beta-lactamase inhibitor combinations. J Antimicrob Chemother. 1993, 31 Suppl A:9-21. 10.1093\/jac\/31.suppl_a.9","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.09.002","article-title":"Development of a twice daily dosing regimen of amoxicillin\/clavulanate","volume":"30 Suppl 2","author":"Bax R","year":"2007","unstructured":"Bax R. Development of a twice daily dosing regimen of amoxicillin\/clavulanate. Int J Antimicrob Agents. 2007, 30 Suppl 2:S118-21. 10.1016\/j.ijantimicag.2007.09.002","journal-title":"Int J Antimicrob Agents"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(80)91118-6","article-title":"Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study","volume":"315","author":"Ball AP","year":"1980","unstructured":"Ball AP, Davey PG, Geddes AM. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study. Lancet. 1980, 315:620-3. 10.1016\/s0140-6736(80)91118-6","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.5.852","article-title":"Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus","volume":"11","author":"Reading C","year":"1977","unstructured":"Reading C, Cole M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977, 11:852-7. 10.1128\/AAC.11.5.852","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3126\/ajms.v13i8.40685","article-title":"Amoxicillin+clavulanic acid in community acquired pneumonia: past, present, and future from an Indian perspective","volume":"13","author":"Budhiraja S","year":"2022","unstructured":"Budhiraja S, Agarwal A, Chugh Y, et al.. Amoxicillin+clavulanic acid in community acquired pneumonia: past, present, and future from an Indian perspective. Asian J Med Sci. 2022, 13:235-44. 10.3126\/ajms.v13i8.40685","journal-title":"Asian J Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.02.005","article-title":"Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective","volume":"14","author":"Mouton JW","year":"2011","unstructured":"Mouton JW, Ambrose PG, Canton R, et al.. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat. 2011, 14:107-17. 10.1016\/j.drup.2011.02.005","journal-title":"Drug Resist Updat"},{"key":"ref15","article-title":"Amoxicillin","author":"Akhavan BJ","year":"2024","unstructured":"Akhavan BJ, Khanna NR, Vijhani P. Amoxicillin. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802527984","article-title":"Amoxicillin and amoxicillin plus clavulanate: a safety review","volume":"8","author":"Salvo F","year":"2009","unstructured":"Salvo F, De Sarro A, Caputi AP, Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009, 8:111-8. 10.1517\/14740330802527984","journal-title":"Expert Opin Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07557.x","article-title":"Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate","volume":"156","author":"Bonifaz A","year":"2007","unstructured":"Bonifaz A, Flores P, Sa\u00fal A, Carrasco-Gerard E, Ponce RM. Treatment of actinomycetoma due to Nocardia spp. with amoxicillin-clavulanate. Br J Dermatol. 2007, 156:308-11. 10.1111\/j.1365-2133.2006.07557.x","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1178373","article-title":"Treatment of cutaneous actinomycosis with amoxicillin\/clavulanic acid","volume":"28","author":"Bonifaz A","year":"2017","unstructured":"Bonifaz A, Tirado-S\u00e1nchez A, Calder\u00f3n L, Montes de Oca G, Torres-Camacho P, Ponce RM. Treatment of cutaneous actinomycosis with amoxicillin\/clavulanic acid. J Dermatolog Treat. 2017, 28:59-64. 10.1080\/09546634.2016.1178373","journal-title":"J Dermatolog Treat"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1111\/j.1742-1241.1999.tb11740.x","article-title":"Efficacy of twice-daily amoxycillin\/clavulanate in lower respiratory tract infections","volume":"53","author":"Balgos AA","year":"1999","unstructured":"Balgos AA, Rodriguez-Gomez G, Nasnas R, et al.. Efficacy of twice-daily amoxycillin\/clavulanate in lower respiratory tract infections. Int J Clin Pract. 1999, 53:325-30.","journal-title":"Int J Clin Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.124.8.921","article-title":"A combination of amoxicillin and clavulanate every 12 hours vs every 8 hours for treatment of acute bacterial maxillary sinusitis","volume":"124","author":"Seggev JS","year":"1998","unstructured":"Seggev JS, Enrique RR, Brandon ML, Larsen LS, Van Tuyl RA, Rowinski CA. A combination of amoxicillin and clavulanate every 12 hours vs every 8 hours for treatment of acute bacterial maxillary sinusitis. Arch Otolaryngol Head Neck Surg. 1998, 124:921-5. 10.1001\/archotol.124.8.921","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3323-3331.2004","article-title":"Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000\/125 milligrams) versus those of amoxicillin-clavulanate (875\/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults","volume":"48","author":"File TM Jr","year":"2004","unstructured":"File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000\/125 milligrams) versus those of amoxicillin-clavulanate (875\/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2004, 48:3323-31. 10.1128\/AAC.48.9.3323-3331.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki480","article-title":"Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin\/clavulanate (2000\/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae","volume":"57","author":"Siquier B","year":"2006","unstructured":"Siquier B, S\u00e1nchez-Alvarez J, Garc\u00eda-Mendez E, et al.. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin\/clavulanate (2000\/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2006, 57:536-45. 10.1093\/jac\/dki480","journal-title":"J Antimicrob Chemother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.153-160.2005","article-title":"Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000\/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875\/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis","volume":"49","author":"Sethi S","year":"2005","unstructured":"Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000\/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875\/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob Agents Chemother. 2005, 49:153-60. 10.1128\/AAC.49.1.153-160.2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/472470","article-title":"Amoxicillin\/clavulanic acid for the treatment of odontogenic infections: a randomised study comparing efficacy and tolerability versus clindamycin","volume":"2015","author":"Tancawan AL","year":"2015","unstructured":"Tancawan AL, Pato MN, Abidin KZ, et al.. Amoxicillin\/clavulanic acid for the treatment of odontogenic infections: a randomised study comparing efficacy and tolerability versus clindamycin. Int J Dent. 2015, 2015:472470. 10.1155\/2015\/472470","journal-title":"Int J Dent"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.19778","article-title":"Comparative trial between the use of amoxicillin and amoxicillin clavulanate in the removal of third molars","volume":"19","author":"Iglesias-Mart\u00edn F","year":"2014","unstructured":"Iglesias-Mart\u00edn F, Garc\u00eda-Perla-Garc\u00eda A, Ya\u00f1ez-Vico R, et al.. Comparative trial between the use of amoxicillin and amoxicillin clavulanate in the removal of third molars. Med Oral Patol Oral Cir Bucal. 2014, 19:e612-5. 10.4317\/medoral.19778","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1111\/j.1742-1241.1999.tb11810.x","article-title":"Cefaclor af versus amoxycillin\/clavulanate in acute bacterial exacerbations of chronic bronchitis: a randomised multicentre study","volume":"53","author":"Bandak SI","year":"1999","unstructured":"Bandak SI, Bolzon LD, Turnak MR, Johns D, Henle SK, Allen BS. Cefaclor af versus amoxycillin\/clavulanate in acute bacterial exacerbations of chronic bronchitis: a randomised multicentre study. Int J Clin Pract. 1999, 53:578-83.","journal-title":"Int J Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0195-6701(05)80009-x","article-title":"Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis","volume":"22","author":"Legnani D","year":"1992","unstructured":"Legnani D, Lombardo VM, Negretto GG, et al.. Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. J Hosp Infect. 1992, 22:69-74. 10.1016\/s0195-6701(05)80009-x","journal-title":"J Hosp Infect"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1995.7.5.432","article-title":"Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis","volume":"7","author":"Cazzola M","year":"1995","unstructured":"Cazzola M, Vinciguerra A, Beghi GF, et al.. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother. 1995, 7:432-41. 10.1179\/joc.1995.7.5.432","journal-title":"J Chemother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1995.7.2.146","article-title":"Efficacy and tolerability of azithromycin versus amoxicillin\/clavulanic acid in acute purulent exacerbation of chronic bronchitis","volume":"7","author":"Beghi G","year":"1995","unstructured":"Beghi G, Berni F, Carrat\u00f9 L, et al.. Efficacy and tolerability of azithromycin versus amoxicillin\/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother. 1995, 7:146-52. 10.1179\/joc.1995.7.2.146","journal-title":"J Chemother"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/158520","article-title":"Levofloxacin-amoxicillin\/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection","volume":"2014","author":"Chen MC","year":"2014","unstructured":"Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin\/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int. 2014, 2014:158520. 10.1155\/2014\/158520","journal-title":"Biomed Res Int"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty CM","year":"2002","unstructured":"Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin\/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther. 2002, 24:1854-70. 10.1016\/s0149-2918(02)80084-4","journal-title":"Clin Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2002.14.5.508","article-title":"Comparison of the efficacy and tolerability of amoxycillin\/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults","volume":"14","author":"Namyslowski G","year":"2002","unstructured":"Namyslowski G, Misiolek M, Czecior E, Malafiej E, Orecka B, Namyslowski P, Misiolek H. Comparison of the efficacy and tolerability of amoxycillin\/clavulanic acid 875 mg b.i.d. with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother. 2002, 14:508-17. 10.1179\/joc.2002.14.5.508","journal-title":"J Chemother"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy12020060","article-title":"Evaluation of oral amoxicillin\/clavulanate for urinary tract infections caused by ceftriaxone non-susceptible Enterobacterales","volume":"12","author":"Salam ME","year":"2024","unstructured":"Salam ME, Jeffres M, Molina KC, Miller MA, Huang M, Fish DN. Evaluation of oral amoxicillin\/clavulanate for urinary tract infections caused by ceftriaxone non-susceptible Enterobacterales. Pharmacy (Basel). 2024, 12:60. 10.3390\/pharmacy12020060","journal-title":"Pharmacy (Basel)"},{"key":"ref34","article-title":"Allergy to betalactams: relationship between chemical structure and antigenicity of molecules","volume":"9","author":"Patriarca G","year":"1999","unstructured":"Patriarca G, D'Ambrosio C, Schiavino D, Nucera E. Allergy to betalactams: relationship between chemical structure and antigenicity of molecules. J Investig Allergol Clin Immunol. 1999, 9:215-21.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref35","unstructured":"Augmentin, Prescribing information, Initial U.S. Approval. 1984. (1984). Accessed: April 22, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050564s053s055,050575s040s042,050597s047s049,050720s026s028...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268637-exploring-the-therapeutic-potential-of-high-dose-co-amoxiclav-1-gm-in-different-clinical-conditions-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T09:54:17Z","timestamp":1721210057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268637-exploring-the-therapeutic-potential-of-high-dose-co-amoxiclav-1-gm-in-different-clinical-conditions-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.64717","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,17]]}}}